Boston Scientific (BSX) Operating Leases (2019 - 2020)

Boston Scientific (BSX) reported Operating Leases of $256.0 million for Q3 2020, down 2.66% sequentially from $263.0 million in Q2 2020.

Boston Scientific (BSX) Operating Leases (2019 - 2020) Analysis & Trends

Boston Scientific (BSX) has 2 years of Operating Leases data on file, last reported at $256.0 million in Q3 2020.

For the quarter ending Q3 2020, Operating Leases changed N/A year-over-year to $256.0 million; the trailing twelve-month figure through Sep 2020 stood at $256.0 million (changed N/A YoY), and the FY2019 full-year result was $276.0 million, changed N/A from the prior year.
Operating Leases slipped to $256.0 million in Q3 2020, from $263.0 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $276.0 million in Q4 2019 to a low of $256.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Steris	20.59 Bn	20.16 Bn	697.10 Mn

Download Data